Etanercept in the treatment of rheumatoid arthritis
Authors Boulos Haraoui, Vivian Bykerk
Published 15 March 2007 Volume 2007:3(1) Pages 99—105
Boulos Haraoui1, Vivian Bykerk2
1Clinical Associate Professor of Medicine, University of Montreal, Montreal Canada; 2Associate Professor of Medicine, University of Toronto, Toronto Canada
Abstract: Etanercept (ETN) is the first anti-tumor necrosis factor (TNF) agent to be approved for the treatment of rheumatoid arthritis (RA). Over the last 8 years, several clinical trials have shown its efficacy and safety in established and early RA, as well as a monotherapy or in combination with methotrexate. ETN not only reduces the signs and symptoms of RA, but also retards the progression of radiographic damage and improves the quality of life and function of patients. Its safety profile has been predictable since the first clinical trials with no new major safety concerns. Beyond its efficacy in RA, ETN is also indicated for the treatment of psoriatic arthritis. This current report reviews the evidence and the data in RA and psoriatic arthritis (PsA).
Keywords: etanercept, tumor necrosis factor-α, rheumatoid arthritis, psoriatic arthritis